Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT‑7117 in Subjects With Erythropoietic Protoporphyria

Next Previous
Trial Profile

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT‑7117 in Subjects With Erythropoietic Protoporphyria

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs MT 7117 (Primary)
  • Indications Erythropoietic protoporphyria
  • Focus Therapeutic Use
  • Acronyms ENDEAVOR
  • Sponsors Mitsubishi Tanabe Pharma America

    • Most Recent Events

    • 30 Jan 2019 Planned End Date changed from 1 Mar 2019 to 1 Dec 2019.
    • 30 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Sep 2018.
    • 10 Jul 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top